Coherus BioSciences Inc (CHRS)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $81.21M
Last updated: Nov 17, 2026 at 11:04 AM ET
Performance (10Y)
Upcoming Estimates
Key Metrics
Technical Indicators Dashboard
As of Nov 16, 2026, the price is 51.4% below its 50-day moving average, and the 50-day average is below the 200-day average. The 14-day RSI is 27.7, below 30, the oversold line.
Moving Averages
MACD
ADX
Aroon & PSAR
Bollinger Bands
RSI (14-Day)
Momentum Oscillators
Volatility Measures
Volume Flow
Volume Metrics
Pivot Points
Advanced Oscillators
Financial Performance
Related GNG Research
No research available
Be the first to write about CHRS
News
CHRS Valuation
GNG's valuation label for CHRS is Undervalued. It trades at 41.1x forward earnings.
- Forward P/E
- 41.1x
- P/B
- 3.1x
CHRS Profitability: Margins, ROIC and FCF
Coherus BioSciences (CHRS) has a gross margin of 69.8%, an operating margin of -271.1% and a net margin of -253.4%. It posts -144.8% ROIC and a -323.9% FCF margin.
- Gross margin
- 69.8%
- Operating margin
- -271.1%
- Net margin
- -253.4%
- ROIC
- -144.8%
- ROE
- -275.2%
- FCF margin
- -323.9%
Coherus BioSciences Competitors
The companies most similar to Coherus BioSciences (CHRS) include Heron Therapeuti, TuHURA Biosciences and Seer.
Sector: Healthcare
Companies most similar to Coherus BioSciencesCHRS Analyst Ratings
Coherus BioSciences (CHRS) has a Buy consensus from 6 analysts: 5 Buy or Strong Buy, 1 Hold and 0 Sell or Strong Sell.
- Consensus
- Buy
- Analysts
- 6
- Strong Buy
- 1
- Buy
- 4
- Hold
- 1
- Sell
- 0
- Strong Sell
- 0
CHRS Bull Case vs Bear Case
Bull case
- CHRS grew quarterly revenue 23.4% year over year.
- 83.3% of CHRS's analyst ratings are Buy or Strong Buy.
Bear case
- CHRS has a -253.4% net profit margin.
- CHRS beat EPS estimates in 12.5% of its last 8 reported quarters.
- CHRS has a debt-to-equity ratio of 2.1x.
CHRS Earnings: Beat Rate and Next Report
Coherus BioSciences (CHRS) beat the EPS estimate in 1 of the last 8 quarters (12.5%). Its next report is expected on Mar 8, 2027.
- Beat rate
- 1 of 8 quarters (12.5%)
- Average surprise
- -36.4%
- EPS estimate (fiscal period ending Dec 31, 2026)
- -$0.22
CHRS Earnings Date
CHRS reports Mar 8, 2027. The date is estimated.
CHRS Earnings Call
The latest CHRS earnings call transcript on file is labeled 2026Q3.
Read the 2026Q3 transcriptCHRS ETF Holders
GNG tracks 6 ETFs that hold CHRS. The largest weights:
- Vanguard Total Stock Market Index Fund Admiral Shares (VTSAX), <0.01% of the fund
- iShares Russell 2000 ETF (IWM), <0.01% of the fund
- Schwab U.S. Broad Market ETF (SCHB), <0.01% of the fund
- Vanguard Morningstar Total Stock Market ETF (VTI), <0.01% of the fund
- Vanguard Russell 2000 Index Fund ETF Shares (VTWO), <0.01% of the fund
Updated Nov 9, 2026. Built from end-of-day prices, company filings and consensus analyst estimates. Methodology
Frequently Asked Questions About CHRS
When does CHRS report earnings?
Coherus BioSciences Inc (CHRS) is expected to report earnings on Mar 8, 2027.
Does CHRS pay dividends?
Coherus BioSciences Inc (CHRS) does not currently pay a regular dividend.
What is CHRS's market cap?
Coherus BioSciences Inc (CHRS) has a market capitalization of $81.21M with a current stock price of $0.51.
CHRS pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors
Get full access to GNG Research
Create a free account to access portfolio tracking, advanced tools, and more.